Singapore markets closed
  • Straits Times Index

    3,161.22
    -5.72 (-0.18%)
     
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow

    34,935.47
    -149.03 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.62 (-0.71%)
     
  • BTC-USD

    39,625.94
    -2,273.67 (-5.43%)
     
  • CMC Crypto 200

    966.43
    +16.53 (+1.74%)
     
  • FTSE 100

    7,108.49
    +76.19 (+1.08%)
     
  • Gold

    1,811.40
    -5.80 (-0.32%)
     
  • Crude Oil

    73.05
    -0.90 (-1.22%)
     
  • 10-Yr Bond

    1.2390
    0.0000 (0.00%)
     
  • Nikkei

    27,781.02
    +497.43 (+1.82%)
     
  • Hang Seng

    26,235.80
    +274.77 (+1.06%)
     
  • FTSE Bursa Malaysia

    1,493.00
    -1.60 (-0.11%)
     
  • Jakarta Composite Index

    6,096.54
    +26.50 (+0.44%)
     
  • PSE Index

    6,446.31
    +176.08 (+2.81%)
     

Coronavirus vaccine maker CureVac plans U.S. listing in July

·1-min read

BERLIN (Reuters) - German vaccine maker CureVac plans to raise funds by selling stock in an initial public offering in the United States next month, a finance ministry document seen by Reuters on Monday showed.

The German government plans to take a stake of about 23% in unlisted CureVac to help fund the biotech company's further development of a COVID-19 vaccine.

The finance ministry said in a letter to parliament's budget committee dated June 15: "It (CureVac) currently has a big capital requirement and plans a flotation on the Nasdaq in New York in July 2020."

European biotech firms prefer Nasdaq because the U.S. capital market offers a critical mass of highly specialised biopharma investors, analysts say. German biotech firms BioNtech and Morphosys have recently sought U.S. listings.

(Reporting by Holger Hansen; Writing by Joseph Nasr; Editing by Edward Taylor and Mark Potter)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting